CHMP Backs Less Frequent Regeneron's Libtayo Dosing Across Approved Cancer Indications In Europe

A report found 15 biotech companies, including ThermoFisher and MilliporeSigma, manipulated antibody assay images. Regeneron's free gene therapy for hearing loss sparked debate. Novartis faced setbacks with failed trials. FDA introduced fast-track programs for ultra-rare diseases and a PreCheck initiative for drug manufacturing.

The EU drug regulator's expert panel endorsed six new medicines and five label expansions in October 2026, benefiting Eli Lilly, Pfizer, and Johnson & Johnson. Lilly's weight loss pill Foundayo and Pfizer's breast cancer therapy Tukysa received positive opinions. Johnson & Johnson's cancer therapy Talvey was recommended for an indication extension. Other companies like Ionis, Regeneron, and Revolution Medicines also received positive opinions for their respective drugs.

Regeneron (REGN) announced the EMA's CHMP recommended approval for an extended dosing schedule of Libtayo (cemiplimab) across all approved indications. The new regimen includes a higher dose every six weeks after an initial 12-week regimen. The European Commission is expected to make a final decision in the coming months.

Regeneron Pharmaceuticals (NASDAQ: REGN) announced on 16 October 2026 that the European Medicines Agency's CHMP recommended a less frequent dosing schedule for its cancer drug Libtayo, moving from every three weeks to every six weeks after an initial 12-week period. The change, if approved by the European Commission, would apply across all of Libtayo's approved cancer indications in the EU.

Regeneron's Libtayo (cemiplimab) received a positive opinion from the EMA's CHMP for an alternative dosing schedule. The new regimen includes a 700 mg dose every six weeks after an initial 12-week regimen of 350 mg every three weeks, with a potential 15- to 30-minute infusion time for the 350 mg dose. The European Commission is expected to make a final decision in the coming months.

Regeneron Pharmaceuticals (REGN) reported 84-week Phase III efficacy data for its treatment of fibrodysplasia ossificans progressiva (FOP). The results are part of ongoing clinical trials. According to the company, the data supports the treatment's long-term effectiveness. REGN's stock may be impacted by these clinical developments.